Tarlatamab-Is Imdelltra reimbursed by medical insurance?

Tarlatamab-Imdelltra, as a new bispecific antibody drug, has not yet been officially launched in China, so domestic medical insurance has not yet included it in the scope of reimbursement. The prerequisite for national medical insurance reimbursement is that the drug must be approved for marketing by the national drug regulatory department and complete the evaluation process of the relevant reimbursement catalog. Since Imdelltra is still awaiting approval in the country, patients are temporarily unable to obtain treatment costs through medical insurance reimbursement.

In the international market, the United States has approved the drug for marketing inMay 2024, but the medical insurance policies of various countries vary greatly. Even in the United States, inclusion in insurance reimbursement needs to be determined based on local health insurance plans and individual patient conditions. Talatumumab is generally priced at a higher price, which means that patients need to bear a greater financial burden if it is not covered by medical insurance. Therefore, for domestic patients, waiting for domestic launch and medical insurance inclusion will be an important prerequisite for economic accessibility of the drug.

From a clinical management perspective, the lack of inclusion in medical insurance also means that doctors need to comprehensively consider the patient's financial status, disease progression, and alternative treatment options when formulating treatment plans. Some patients may have access to the drug through clinical trials or international patient assistance programs, but these channels are subject to limited quantities and restricted use. Therefore, medical insurance policies and the launch process will directly affect the accessibility and promotion and application of talatumumab in China.

In general, talatumumab has not yet been included in medical insurance reimbursement in China. Patients need to obtain the drug through legal channels and wait for official approval for marketing and medical insurance inclusion information. Medical institutions and doctors should reasonably plan patient treatment plans based on existing treatment guidelines, and pay attention to future adjustments to medical insurance policies to ensure that patients can use the drug safely and easily.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html